Shots:
- Takeda has reported data from 2 global P-III trials (NCT06088043 & NCT06108544) assessing zasocitinib (TAK-279) vs apremilast & PBO in 693 & 1108 adult pts, respectively, with mod. to sev. PsO
- Trial showed superiority to PBO on co-1EPs (sPGA 0/1 & PASI 75) at Wk. 16, with early PASI 75 responses from Wk. 4, sustained through Wk. 24, & improvements across all 44 2EPs vs PBO & apremilast, with >50% pts reaching PASI 90 & ~30% pts achieving PASI 100 at 16wks.
- Takeda plans to submit an NDA to the FDA & other regulatory authorities in 2026, plus zasocitinib is also being evaluated in an H2H trial against Sotyktu for PsO, a P-III trial for PsA & P-II trials for Crohn’s disease & ulcerative colitis
Ref: Takeda | Image: Takeda | Press Release
Related News: Takeda Partners with Innovent Biologics to Boost Oncology Pipeline with Advanced Solid Tumor Therapies
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
